Teva Pharmaceutical Industries Limited
TEVA
$16.71
$0.382.33%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -5.12% | 12.52% | 7.37% | 4.32% | 14.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.12% | 12.52% | 7.37% | 4.32% | 14.75% |
| Cost of Revenue | 3.33% | 9.20% | 2.79% | -1.49% | -3.41% |
| Gross Profit | -12.25% | 16.10% | 12.69% | 11.95% | 36.42% |
| SG&A Expenses | 5.54% | 9.48% | 3.19% | 5.23% | 7.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -22.22% | -171.43% | 95.83% | -342.86% | -57.65% |
| Total Operating Expenses | 4.05% | 7.74% | 4.33% | -0.09% | -1.20% |
| Operating Income | -28.62% | 31.93% | 21.94% | 32.26% | 95.77% |
| Income Before Tax | -148.62% | -593.85% | 73.46% | -73.16% | 142.44% |
| Income Tax Expenses | -31.71% | 675.00% | 4,037.50% | -173.68% | -72.48% |
| Earnings from Continuing Operations | -158.89% | -606.49% | 3.53% | -65.61% | 134.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1,550.00% | -487.50% | -17.14% | 748.48% | -112.50% |
| Net Income | -146.87% | -733.33% | 2.98% | 36.82% | 135.24% |
| EBIT | -28.62% | 31.93% | 21.94% | 32.26% | 95.77% |
| EBITDA | -23.40% | 20.98% | 10.93% | 16.06% | 60.53% |
| EPS Basic | -146.37% | -726.14% | 4.10% | 37.25% | 134.92% |
| Normalized Basic EPS | -23.78% | 38.81% | 35.06% | 189.64% | 121.35% |
| EPS Diluted | -147.46% | -750.00% | 3.85% | 38.10% | 134.12% |
| Normalized Diluted EPS | -22.69% | 40.54% | 35.06% | 189.64% | 118.25% |
| Average Basic Shares Outstanding | 1.07% | 1.07% | 1.16% | 0.72% | 0.90% |
| Average Diluted Shares Outstanding | -0.35% | -0.18% | 1.16% | 0.72% | 2.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
